PepGen’s Mid-Stage Myotonic Dystrophy Study Hit With ‘Surprise’ Pause
The timing of the partial hold is “odd,” according to analysts at Stifel, who noted that the preclinical data the FDA took issue with were filed in mid-2024.
PepGen’s Mid-Stage Myotonic Dystrophy Study Hit With ‘Surprise’ Pause Read More »
